Absence of amyloid β oligomers at the postsynapse and regulated synaptic Zn2+in cognitively intact aged individuals with Alzheimer's disease neuropathology

Molecular Neurodegeneration

Volumn 7, Issue 1, 2012, Pages

  Bjorklund, Nicole L ^a   Reese, Lindsay C ^a   Sadagoparamanujam, V M ^a   Ghirardi, Valeria ^a   Woltjer, Randall L ^b   Taglialatela, Giulio ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Asymptomatic; A oligomers; Hippocampus; Synaptic vesicle; Zinc

Indexed keywords

AMYLOID BETA PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GRAPHITE; OLIGOMER; ZINC;

AGED; ALZHEIMER DISEASE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL FRACTIONATION; COGNITION; CONTROLLED STUDY; FEMALE; FURNACE; HIPPOCAMPUS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MINI MENTAL STATE EXAMINATION; MOLECULAR WEIGHT; NERVE CELL PLASTICITY; NEUROPATHOLOGY; POSTSYNAPTIC DENSITY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SYNAPSE; SYNAPSE VESICLE; VERY ELDERLY; COGNITIVE DEFECT; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BLOTTING, WESTERN; COGNITION DISORDERS; FEMALE; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; SYNAPSES; ZINC;

EID: 84861428833     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-7-23     Document Type: Article

References (67)

1. Alzheimer's A: Alzheimer's disease facts and figures. Alzheimer's & Dementia 2010, 2010:6.
2. Hardy J, Allsop D: Amyloid deposition as the central event in the etiology of Alzheimer's disease. Trends Pharmacol Sci 1991, 12:383-388.
3. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991, 82:239-259.
4. Kramer PL, Xu H, Woltjer RL, Westaway SK, Clark D, Erten-Lyons D, Kaye JA, Welsh-Bohmer KA, Troncoso JC, Markesbery WR, et al: Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study. Neurobiol Aging 2011, 32:2113-2122.
5. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J: Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999, 155:853-862. (Pubitemid 29426831)
6. Erten-Lyons D, Woltjer RL, Dodge H, Nixon R, Vorobik R, Calvert JF, Leahy M, Montine T, Kaye J: Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology 2009, 72:354-360.
7. Riudavets MA, Iacono D, Resnick SM, O'Brien R, Zonderman AB, Martin LJ, Rudow G, Pletnikova O, Troncoso JC: Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol Aging 2007, 28:1484-1492. (Pubitemid 47238539)
8. Iacono D, O'Brien R, Resnick SM, Zonderman AB, Pletnikova O, Rudow G, An Y, West MJ, Crain B, Troncoso JC: Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol 2008, 67:578-589. (Pubitemid 351787084)
9. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al: National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol 2012, 123:1-11.
10. Lesne S: Koh Ming T, Kotilinek L, Kayed R, Glabe Charles G, Yang A, Gallagher M, Ashe Karen H: A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
11. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005, 8:79-84. (Pubitemid 41236735)
12. Reese LC, Zhang W, Dineley KT, Kayed R, Taglialatela G: Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell 2008, 7:824-835. (Pubitemid 352749437)
13. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG: Calcium Dysregulation and Membrane Disruption as a Ubiquitous Neurotoxic Mechanism of Soluble Amyloid Oligomers. J Biol Chem 2005, 280:17294-17300. (Pubitemid 41389198)
14. Poling A, Morgan-Paisley K, Panos John J, Kim E-M, O'Hare E, Cleary James P, Lesne S, Ashe Karen H, Porritt M, Baker Lisa E: Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures. Behavioural brain research 2008, 193:230-234.
15. O'Shea SD, Smith IM, McCabe OM, Cronin MM, Walsh DM, O'Connor WT: Intracerebroventricular administration of amyloid β-protein oligomers selectively increases dorsal hippocampal dialysate glutamate levels in the awake rat. Sensors 2008, 8:7428-7437.
16. Dineley KT, Kayed R, Neugebauer V, Fu Y, Zhang W, Reese LC, Taglialatela G: Amyloid-β oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res 2010, 88:2923-2932.
17. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL: Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 2007, 27:796-807. (Pubitemid 46174498)
18. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, et al: Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A 2009, 106:4012-4017.
19. Grabrucker AM, Schmeisser MJ, Udvardi PT, Arons M, Schoen M, Woodling NS, Andreasson KI, Hof PR, Buxbaum JD, Garner CC, Boeckers TM: Amyloid beta protein-induced zinc sequestration leads to synaptic loss via dysregulation of the ProSAP2/Shank3 scaffold. Mol Neurodegener 2011, 6:65.
20. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, et al: Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008, 14: 837-842.
21. Abdul HM, Sama MA, Furman JL, Mathis DM, Beckett TL, Weidner AM, Patel ES, Baig I, Murphy MP, LeVine H 3rd: et al: Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci 2009, 29:12957-12969.
22. Moore AN, Waxham MN, Dash PK: Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex. J Biol Chem 1996, 271:14214-14220. (Pubitemid 26190319)
23. Lovell MA: A Potential Role for Alterations of Zinc and Zinc Transport Proteins in the Progression of Alzheimer's Disease. J Alzheimer's Dis 2009, 16:471-483.
24. Watt NT, Whitehouse IJ, Hooper NM: The role of zinc in Alzheimer's disease. Int J Alzheimer's Dis 2011, 2011. Article ID 971021.
25. Noy D, Solomonov I, Sinkevich O, Arad T, Kjaer K, Sagi I: Zinc-Amyloid β Interactions on a Millisecond Time-Scale Stabilize Non-fibrillar Alzheimer-Related Species. J Am Chem Soc 2008, 130:1376-1383. (Pubitemid 351171018)
26. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J: A role for synaptic zinc in activity-dependent Aβ oligomer formation and accumulation at excitatory synapses. J Neurosci 2009, 29:4004-4015.
27. Danscher G, Jensen KB, Frederickson CJ, Kemp K, Andreasen A, Juhl S, Stoltenberg M, Ravid R: Increased amount of zinc in the hippocampus and amygdala of Alzheimer's diseased brains: a proton-induced X-ray emission spectroscopic analysis of cryostat sections from autopsy material. J Neurosci Methods 1997, 76:53-59. (Pubitemid 27405086)
28. Deibel MA, Ehmann WD, Markesbery WR: Copper, iron, and zinc imbalances in severely degenerated brain regions in Alzheimer's disease: Possible relation to oxidative stress. J Neurol Sci 1996, 143:137-142. (Pubitemid 26402800)
29. Religa D, Strozyk D, Cherny RA, Volitakis I, Haroutunian V, Winblad B, Naslund J, Bush AI: Elevated cortical zinc in Alzheimer disease. Neurology 2006, 67:69-75. (Pubitemid 44305464)
30. Beyer N, Coulson DT, Heggarty S, Ravid R, Irvine GB, Hellemans J, Johnston JA: ZnT3 mRNA levels are reduced in Alzheimer's disease post-mortem brain. Mol Neurodegener 2009, 4:53.
31. Uchida Y, Takio K, Titani K, Ihara Y, Tomonaga M: The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron 1991, 7:337-347.
32. Adlard PA, Parncutt JM, Finkelstein DI, Bush AI: Cognitive loss in zinc transporter-3 knock-out mice: a phenocopy for the synaptic and memory deficits of Alzheimer's disease?. J Neurosci 2010, 30:1631-1636.
33. Yu WH, Lukiw WJ, Bergeron C, Niznik HB, Fraser PE: Metallothionein III is reduced in Alzheimer's disease. Brain Res 2001, 894:37-45. (Pubitemid 32197596)
34. Cousins RJ, Liuzzi JP, Lichten LA: Mammalian zinc transport, trafficking, and signals. J Biol Chem 2006, 281:24085-24089. (Pubitemid 44274182)
35. Assaf SY, Chung SH: Release of endogenous Zn2+ from brain tissue during activity. Nature 1984, 308:734-736. (Pubitemid 14127670)
36. Colvin RA, Davis N, Nipper RW, Carter PA: Zinc transport in the brain: routes of zinc influx and efflux in neurons. J Nutr 2000, 130:1484S-1487S. (Pubitemid 30244149)
37. Amico-Ruvio SA, Murthy SE, Smith TP, Popescu GK: Zinc Effects on NMDA Receptor Gating Kinetics. Biophys J 2011, 100:1910-1918.
38. Harrison NL, Gibbons SJ: Zn2+: an endogenous modulator of ligand- and voltage-gated ion channels. Neuropharmacology 1994, 33:935-952.
39. Mathie A, Sutton GL, Clarke CE, Veale EL: Zinc and copper: pharmacological probes and endogenous modulators of neuronal excitability. Pharmacol Ther 2006, 111:567-583. (Pubitemid 44118429)
40. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ: Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 2001, 276:20466-20473.
41. Karr JW, Akintoye H, Kaupp LJ, Szalai VA: N-Terminal Deletions Modify the Cu2+ Binding Site in Amyloid-β. Biochemistry 2005, 44:5478-5487. (Pubitemid 40489987)
42. Liu S-T, Howlett G, Barrow CJ: Histidine-13 Is a Crucial Residue in the Zinc Ion-Induced Aggregation of the Aβ Peptide of Alzheimer's Disease. Biochemistry 1999, 38:9373-9378.
43. Lim KH, Kim YK, Chang Y-T: Investigations of the Molecular Mechanism of Metal-Induced Aβ (1-40) Amyloidogenesis. Biochemistry 2007, 46:13523-13532.
44. Bush AI, Pettingell WH, Multhaup G: Paradis Md, Vonsattel J-P, Gusella JF, Beyreuther K, Masters CL, Tanzi RE: Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 1994, 265:1464-1467.
45. 2 adhesiveness and secretase site cleavage by zinc. J Biol Chem 1994, 269:12152-12158.
46. Green MS, Kaye JA, Ball MJ: The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old. Neurology 2000, 54:105-113. (Pubitemid 30038746)
47. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL: Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 1999, 46:860-866.
48. Naslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, et al: Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 1994, 91:8378-8382. (Pubitemid 24273667)
49. Selkoe DJ: Alzheimer's Disease Is a Synaptic Failure. Science 2002, 298:789-791.
50. Phillips GR, Huang JK, Wang Y, Tanaka H, Shapiro L, Zhang W, Shan W-S, Arndt K, Frank M, Gordon RE, et al: The presynaptic particle web: ultrastructure, composition, dissolution, and reconstitution. Neuron 2001, 32:63-77. (Pubitemid 32995890)
51. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, et al: Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 2004, 24:10191-10200. (Pubitemid 39492046)
52. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, Khuon D, Gong Y, Bigio EH, Shaw P, et al: Monoclonal antibodies that target pathological assemblies of Aβ. J Neurochem 2007, 100:23-35. (Pubitemid 46085837)
53. Bito H, Takemoto-Kimura S: Ca2+/CREB/CBP-dependent gene regulation: a shared mechanism critical in long-term synaptic plasticity and neuronal survival. Cell Calcium 2003, 34:425-430. (Pubitemid 37021234)
54. Bitanihirwe BKY, Cunningham MG: Zinc: the brain's dark horse. Synapse 2009, 63:1029-1049.
55. Frederickson CJ, Suh SW, Silva D, Thompson RB: Importance of zinc in the central nervous system: the zinc-containing neuron. J Nutr 2000, 130:1471S-1483S. (Pubitemid 30244148)
56. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ: Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol 2006, 572: 477-492.
57. Silva AJ, Kogan JH, Frankland PW, Kida S: CREB and memory. Annu Rev Neurosci 1998, 21:127-148. (Pubitemid 28150661)
58. Stoltenberg M, Bruhn M, Sondergaard C, Doering P, West MJ, Larsen A, Troncoso JC, Danscher G: Immersion autometallographic tracing of zinc ions in Alzheimer beta-amyloid plaques. Histochem Cell Biol 2005, 123:605-611. (Pubitemid 41126079)
59. Suh SW, Jensen KB, Jensen MS, Silva DS, Kesslak PJ, Danscher G, Frederickson CJ: Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res 2000, 852:274-278. (Pubitemid 30035163)
60. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
61. Folstein MF, Folstein SE, McHugh PR: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189-198.
62. Romijn HJ, van Uum JF, Breedijk I, Emmering J, Radu I, Pool CW: Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. J Histochem Cytochem 1999, 47:229-236.
63. Bjorklund NL, Sadagoparamanujam VM, Taglialatela G: Selective, quantitative measurement of releasable synaptic zinc in human autopsy hippocampal brain tissue from Alzheimer's disease patients. J Neurosci Methods 2012, 203:146-151.
64. Henriques AG, Vieira SI, da Cruz E Silva EF, da Cruz E Silva OA: Aβ promotes Alzheimer's disease-like cytoskeleton abnormalities with consequences to APP processing in neurons. J Neurochem 2010, 113:761-771.
65. Wang Q, Woltjer RL, Cimino PJ, Pan C, Montine KS, Zhang J, Montine TJ: Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J 2005, 19:869-871. 810.1096/fj.1004-3210fje.
66. Aldridge GM, Podrebarac DM, Greenough WT, Weiler IJ: The use of total protein stains as loading controls: An alternative to high-abundance single-protein controls in semi-quantitative immunoblotting. J Neurosci Methods 2008, 172:250-254.
67. Alcock NW: A hydrogen-peroxide digestion system for tissue trace-metal analysis. Biol Trace Elem Res 1987, 13:363-370.